Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Hoffman

Showing results (131-140 of 204) with videos related to

Pageof 21
Sort By:
The Journal of Clinical Investigation|October 2, 2012
Spleens of myelofibrosis patients contain malignant hematopoietic stem cellsXiaoli Wang, Sonam Prakash, Min Lu, et al.
Leukemia & Lymphoma|November 13, 2019
Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysisDouglas Tremblay, Amber King, Lihua Li, et al.
Experimental Hematology|February 2, 2002
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivoAmelia Bartholomew, Cord Sturgeon, Mandy Siatskas, et al.
Experimental Hematology|January 22, 2008
Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the diseaseAnna Rita Migliaccio, Fabrizio Martelli, Maria Verrucci, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 8, 2016
Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative NeoplasmsIrum Khan, Ardaman Shergill, Santosh L Saraf, et al.
Scientific Reports|November 14, 2019
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative NeoplasmsManali Sapre, Douglas Tremblay, Eric Wilck, et al.
Experimental Hematology|July 21, 2009
Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasmsXiaoli Wang, Amanda LeBlanc, Steven Gruenstein, et al.
Leukemia Research|December 9, 2016
A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)John Mascarenhas, Lonette Sandy, Min Lu, et al.
Pediatric Blood & Cancer|December 31, 2020
Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemiaNicole Kucine, Shayla Bergmann, Spencer Krichevsky, et al.
Blood|June 7, 2019
Oral idasanutlin in patients with polycythemia veraJohn Mascarenhas, Min Lu, Heidi Kosiorek, et al.
Pageof 21

Showing results (131-140 of 204) with videos related to

Sort By:
Pageof 21
The Journal of Clinical Investigation|October 2, 2012
Spleens of myelofibrosis patients contain malignant hematopoietic stem cellsXiaoli Wang, Sonam Prakash, Min Lu, et al.
Leukemia & Lymphoma|November 13, 2019
Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysisDouglas Tremblay, Amber King, Lihua Li, et al.
Experimental Hematology|February 2, 2002
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivoAmelia Bartholomew, Cord Sturgeon, Mandy Siatskas, et al.
Experimental Hematology|January 22, 2008
Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the diseaseAnna Rita Migliaccio, Fabrizio Martelli, Maria Verrucci, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 8, 2016
Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative NeoplasmsIrum Khan, Ardaman Shergill, Santosh L Saraf, et al.
Scientific Reports|November 14, 2019
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative NeoplasmsManali Sapre, Douglas Tremblay, Eric Wilck, et al.
Experimental Hematology|July 21, 2009
Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasmsXiaoli Wang, Amanda LeBlanc, Steven Gruenstein, et al.
Leukemia Research|December 9, 2016
A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)John Mascarenhas, Lonette Sandy, Min Lu, et al.
Pediatric Blood & Cancer|December 31, 2020
Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemiaNicole Kucine, Shayla Bergmann, Spencer Krichevsky, et al.
Blood|June 7, 2019
Oral idasanutlin in patients with polycythemia veraJohn Mascarenhas, Min Lu, Heidi Kosiorek, et al.
Pageof 21